Plaque Psoriasis – (ME3183-3)

Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects with Moderate to Severe Plaque Psoriasis

Register Today!</a

Trial Information

Start DateFall 2022
End DateTBD
Trial Duration2 years
Number of Visits9
Lead CRCMarija Bernstein

For additional information
on this trial contact: